Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.52 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.43 |
| ▸ | ABCC1 | P33527 | 3/20 | 0.43 |
| ▸ | DRD2 | P14416 | 3/20 | 0.42 |
| ▸ | HRH1 | P35367 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 3/20 | 0.42 |
| ▸ | PPARA | Q07869 | 3/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | SMO | Q99835 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2995819 | 0.90 | ALOX5AP (0.47) | HRH3ALOX5APABCB1ABCC1DRD2 | |
| SCHEMBL2990949 | 0.90 | ALOX5AP (0.47) | HRH3ALOX5APABCB1ABCC1DRD2 | |
| SCHEMBL2991267 | 0.90 | ALOX5AP (0.45) | HRH3ALOX5APABCB1ABCC1DRD2 | |
| SCHEMBL3000988 | 0.87 | ALOX5AP (0.43) | HRH3ALOX5APABCB1ABCC1DRD2 | |
| SCHEMBL2991929 | 0.85 | ALOX5AP (0.50) | ALOX5APPPARGPPARAFFAR1MAPK14 | |
| SCHEMBL13248455 | 0.85 | ALOX5AP (0.52) | ALOX5APPPARGPPARAFFAR1MAPK14 | |
| SCHEMBL3002907 | 0.84 | ALOX5AP (0.43) | HRH3ALOX5APABCB1ABCC1PPARG | |
| SCHEMBL13248470 | 0.84 | ALOX5AP (0.53) | ALOX5APPPARGPPARAFFAR1MAPK14 | |
| SCHEMBL13267978 | 0.83 | ALOX5AP (0.54) | ALOX5APPPARGPPARAFFAR1MAPK14 | |
| SCHEMBL2993020 | 0.83 | ALOX5AP (0.47) | ALOX5APHRH1PPARAMAPK14SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2546232-A1 | Diphenyl Substituted Alkanes | Merck Sharp & Dohme Corp. (US) | 2013-01-16 | — | — | EP | disclosed |
| US-20100190761-A1 | DIPHENYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME CORP. | 2010-07-29 | — | — | US | disclosed |
| EP-2170065-A1 | DIPHENYL SUBSTITUTED ALKANES | Merck Sharp & Dohme Corp. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008156721-A1 | DIPHENYL SUBSTITUTED ALKANES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190761-A1 | DIPHENYL SUBSTITUTED ALKANES | ALOX5, ALOX15, ALOX15B | HRH3 697/4885ALOX5AP 15/4885ABCB1 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.